All In Biotech

Drug Trial Radar · NCT05474755

To Assess the Efficacy of GP681 Tablet Versus Placebo in Patients With Acute Uncomplicated Influenza Virus Infection

A Multi-center, Randomized, Double-blind, Placebo-controlled Phase III Clinical Study on the Safety and Efficacy of GP681 Tablets in the Treatment of Acute Uncomplicated Influenza

Last checked: Nov 19, 2026Latest source record: Nov 14, 2023 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedPivotal-lookingPhase 3. Randomized with 591 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

591

Actual

Start

Jul 28, 2022

Primary completion

Apr 25, 2023

Study completion Oct 31, 2023

Sponsor

Sponsor type
Industry
First posted
Jul 26, 2022

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Double (participant, investigator)
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 5 years, up to 65 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This study will evaluate the efficacy, safety, and population pharmacokinetics of a single, oral dose of GP681 compared with placebo in patients aged 12 to 65 years with acute uncomplicated influenza virus infection

Conditions

  • Influenza

Interventions

  • GP681 40mgDrug

    2X20mg tablets taken orally

  • PlaceboDrug

    Placebo tablets matching GP681 40mg

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Time to alleviation of influenza symptomsTime frame: Up to Day 15

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • The First People's Hospital of Wenling

    Wenling, Zhejiang, China

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.